Bio
Mr. Scherl is a General Partner of NewSpring Capital, with significant experience in principal investing, corporate management and finance, focused exclusively in the health care and life sciences industries. Prior to joining NewSpring in 2003, Mr. Scherl worked with Pequot Ventures, which managed venture funds in excess of $1 billion within Pequot Capital. Previously, he was a member of the health care investment team of Behrman Capital, a private equity investment firm which managed over $700 million. Before entering private equity in 1997, he served as Senior Director, Strategic Planning, for Value Health, the largest independent pharmacy and mental health benefit management company, where he structured multi-year contracts with leading pharmaceutical companies and executed key growth initiatives, prior to its successful sale to Columbia HCA. He also served as U.S. Manager, Pricing Policy at Merck & Co., and prior to that was in the investment banking group at Lehman Brothers. Mr. Scherl is currently a board member of Core Essence Orthopaedics, EKR Therapeutics, Immune Control, and Nitric BioTherapeutics. He was a board member of AppTec Laboratory Services prior to its sale to Wuxi Pharma and Scandius BioMedical prior to its sale to Covidien. He received a BA with honors in economics from Duke University and an MBA from Harvard Business School.
Career
|
NewSpring CapitalEmail: [email protected] |